Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Pal on the Frontline Approval of Nivolumab and Ipilimumab in mRCC

September 15th 2018

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the frontline approval of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic renal cell carcinoma (RCC).

Dr. Grivas on Combination Strategies in Genitourinary Cancer

September 13th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination strategies in genitourinary cancer.

Combinations Poised to Carry Clinical Benefit in RCC

September 13th 2018

Bradley McGregor, MD, discusses the impact of combination therapies on the treatment landscape and highly anticipated studies in renal cell carcinoma.

Dr. Ho on Managing Immune-Related AEs in Kidney Cancer

September 11th 2018

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.

Dr. McGregor on Whether Patients Need Frontline Combinations in RCC

September 11th 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Avelumab/Axitinib Combo Improves PFS in Frontline RCC

September 11th 2018

Combining the PD-L1 inhibitor avelumab with the VEGF inhibitor axitinib significantly improved progression-free survival compared with sunitinib in treatment-naïve patients with advanced renal cell carcinoma, according to findings from the phase III JAVELIN Renal 101 study.

Dr. Gupta Discusses Combination Immunotherapy in RCC

September 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses combination immunotherapy in renal cell carcinoma.

Dr. Figlin Discusses the Future of Kidney Cancer Treatment

September 10th 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the future of kidney cancer treatment.

Sharma Stresses Importance of Refining Immunotherapy in GU Cancers

September 10th 2018

Padmanee Sharma, MD, PhD, shares her insight on the current state of immunotherapy in the treatment of patients with genitourinary cancers.

Dr. Van Veldhuizen on Frontline Immunotherapy for Kidney Cancer

September 7th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

Dr. Agarwal on Next Steps in Kidney Cancer

September 7th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the next steps in the kidney cancer paradigm.

Dr. Balar Discusses Study of Immunotherapy Combination in Bladder Cancer

September 6th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses a study of an immunotherapy combination in bladder cancer.

Dr. Sznol Discusses Immunotherapy in Non-Clear Cell Renal Cancer

September 6th 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy in non-clear cell renal cancer.

Dr. Siefker-Radtke on Next Steps With Erdafitinib in Bladder Cancer

August 31st 2018

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses next steps with erdafitinib in patients with bladder cancer.

Dr. Galsky Discusses Neoadjuvant Immunotherapy in Bladder Cancer

August 22nd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immunotherapy in bladder cancer.

Dr. Van Veldhuizen Reflects on the CARMENA Trial in RCC

August 20th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the impact of the CARMENA trial results in renal cell carcinoma.

Neoadjuvant Immunotherapy Emerges as a New Frontier

August 20th 2018

Although checkpoint blocking immunotherapy has significantly improved outcomes for patients with advanced and metastatic disease, researchers believe the modality also may be effective in the neoadjuvant setting.

Dr. George Discusses an Analysis of the S-TRAC Study in RCC

August 15th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses an analysis of the S-TRAC study in renal cell carcinoma.

Dr. O'Neil on Standard of Care in Muscle-Invasive Bladder Cancer

August 14th 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the current standard of care in muscle-invasive bladder cancer.

Expert Shares Insight on Analyses From S-TRAC Trial in RCC

August 13th 2018

Daniel J. George, MD, discusses an analysis of RCC patients in the S-TRAC trial with the highest risk of recurrence, and potential prognostic factors of DFS that emerged from the study.